Skip to content

The role of MRD in predicting ovarian cancer recurrence and chemosensitivity

The role of MRD in predicting ovarian cancer recurrence and chemosensitivity

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111197
Enrollment
Unknown
Registered
2025-10-28
Start date
2022-11-16
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ShenZhen
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 80 years (inclusive); (2) Patients with ovarian cancer who, after clinical evaluation, can undergo complete tumor resection (R0) via primary cytoreductive surgery, or who can achieve complete resection (R0) via interval cytoreductive surgery following neoadjuvant therapy; (3) Ovarian cancer as a sole diagnosis, without concomitant occurrence of other malignancies; (4) Availability of the patient’s clinical information and definitive pathological diagnosis; (5) Ability to comply with long-term follow-up (20 months postoperatively), including regular re-examinations and blood sample collection; (6) Patient’s consent to participate in the follow-up program and to provide follow-up information; (7) Informed consent obtained from the patient or the patient’s legal representative, and the patient is able to cooperate in completing the requirements of the study.

Exclusion criteria

Exclusion criteria: (1) Patients with severe comorbidities resulting in a life expectancy shorter than the study follow-up period; (2) Patients who have received a blood transfusion within three months prior to enrollment; (3) Patients who are HIV-positive or have other immunodeficiency disorders; (4) Pregnant patients; (5) Patients with alcohol or drug abuse; (6) Any other conditions deemed by the investigators as potentially affecting study outcomes or violating ethical principles.

Design outcomes

Primary

MeasureTime frame
Peripheral blood ctDNA level;Progression free survival;

Countries

China

Contacts

Public ContactLi Sun

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ShenZhen

xjsunli@sina.com+86 755 6661 8168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026